Galvan L, Evans J E, Comis R L, Gottlieb A, Gyorkey F, Lane M, Prestayko A W, Crooke S T
Cancer Res. 1982 Apr;42(4):1562-6.
An accompanying report describes the purification and partial characterization of a unique DNA-binding protein (Mr 64,000; pI 5.9) that is present in human sera. This report gives the results of assays of sera from patients for the bleomycin inhibitor protein (BIP) using the Pseudomonas bacteriophage covalently closed circular DNA fluorescence technique standardized for DNA breakage induced by bleomycin. The results of the BIP assays were expressed by values of specific activity of inhibition. One arbitrary unit of inhibitory activity was defined as equivalent to the amount of serum protein required to cause 50% inhibition of DNA degradation using standard conditions of the DNA breakage assay. The mean values of specific activity of inhibition (SAI) for groups of healthy individuals (n = 26), patients with nonmalignant diseases (n = 33), and patients with malignant diseases (n = 83) were 12.60 +/- 4.69 (S.E.), 12.53 +/- 3.17, and 2.40 +/- 0.84 units/mg, respectively. Mean SAI values for patients with cancers of various types were: solid tumors (n = 46), 2.44 +/- 0.86; leukemias (n = 24), 2.59 +/- 0.96; and lymphomas (n = 18), 2.07 +/- 0.64. The decrease in BIP activity was not correlated with sex, age, or prior chemotherapy. Mean SAI values of male (n = 29) and female (n = 59) patients with cancer were 2.61 +/- 0.87 and 2.30 +/- 0.83 units/mg, respectively. Mean SAI values for different age groups were: 0 to 40 years (n = 21), 2.05 +/- 0.68 units/mg; 41 to 70 years (n = 56), 2.59 +/- 0.68 units/mg; and greater than 70 years (n = 11), 2.12 +/- 0.67 units/mg. Cancer patients with and without prior chemotherapy had mean SAI values of 2.97 +/- 0.85 (n = 23) and 2.20 +/- 0.86 units/mg (n = 65), respectively. Linear regression analysis comparing SAI values and serum protein levels showed no correlation (r = 0.21). These results suggest the decrease of the BIP is associated with malignant disease. Additional controlled studies are required before the significance of this association can be adequately assessed.
一份随附报告描述了从人血清中纯化并部分鉴定出的一种独特的DNA结合蛋白（分子量64,000；等电点5.9）。本报告给出了使用针对博来霉素诱导的DNA断裂标准化的铜绿假单胞菌噬菌体共价闭合环状DNA荧光技术对患者血清中的博来霉素抑制蛋白（BIP）进行检测的结果。BIP检测结果用抑制比活性值表示。一个任意抑制活性单位定义为在DNA断裂检测的标准条件下，导致DNA降解50%抑制所需的血清蛋白量。健康个体组（n = 26）、非恶性疾病患者组（n = 33）和恶性疾病患者组（n = 83）的抑制比活性（SAI）平均值分别为12.60±4.69（标准误）、12.53±3.17和2.40±0.84单位/毫克。各类癌症患者的平均SAI值为：实体瘤（n = 46），2.44±0.86；白血病（n = 24），2.59±0.96；淋巴瘤（n = 18），2.07±0.64。BIP活性的降低与性别、年龄或既往化疗无关。男性（n = 29）和女性（n = 59）癌症患者的平均SAI值分别为2.61±0.87和2.30±0.83单位/毫克。不同年龄组的平均SAI值为：0至40岁（n = 21），2.05±0.68单位/毫克；41至70岁（n = 56），2.59±0.68单位/毫克；大于70岁（n = 11），2.12±0.67单位/毫克。有和没有接受过化疗的癌症患者的平均SAI值分别为2.97±0.85（n = 23）和2.20±0.86单位/毫克（n = 65）。比较SAI值和血清蛋白水平的线性回归分析显示无相关性（r = 0.21）。这些结果表明BIP的降低与恶性疾病有关。在能够充分评估这种关联的意义之前，还需要进行更多的对照研究。
